Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.
Bristol-Myers Squibb (BMS) has challenged the recently released report by the Institute for Clinical and Economic Review (ICER) that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma (MM). In a press release, the company said “We fundamentally disagree with ICER’s approach to value assessment, which led to the questionable conclusions outlined in its report.”
The company’s new treatment for MM, elotozumab (Empliciti), was 1 of 3 agents approved right before the annual meeting of the American Society of Hematology (ASH) in December 2015. Elotozumab, daratumumab (Darzalex), and ixazomib (Ninlaro) were all reviewed during a joint session held by the FDA and ASH. Left with multiple choices, how best can clinicians choose the treatment for their patients in combination with the standard of care?
The ICER report focused on 6 different combination treatments to be used as second or third-line treatments in relapsed/refractory patients with MM. However, the report concluded that while some of these combinations are promising, it’s too early to determine their cost-effectiveness.
BMS has raised objections to several sections of the report, with the patient perspective in mind:
3. It does not adhere to established Health Technology Assessment (HTA) best practices. HTA should be based on a clear, transparent, sophisticated and, differentiated view of value. It should include a clear understanding of disease management and indirect benefits.
“While assessments of cost-effectiveness may prove useful in comparing treatments, they have significant limitations, and the lack of available mature data sources preclude the drawing of valid conclusions,” the release claims.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More